RAGE genetic polymorphisms are associated with risk, chemotherapy response and prognosis in patients with advanced NSCLC
To explore the association between genetic polymorphisms of the receptor for advanced glycation end-products (RAGE) and susceptibility, chemotherapy response rate and prognosis of non-small cell lung cancer (NSCLC). This is a prospective study in which 562 patients with NSCLC and 764 healthy control...
Gespeichert in:
| Veröffentlicht in: | PloS one 2012-10, Vol.7 (10), p.e43734-e43734 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | e43734 |
|---|---|
| container_issue | 10 |
| container_start_page | e43734 |
| container_title | PloS one |
| container_volume | 7 |
| creator | Wang, Xiang Cui, Enhai Zeng, Huazong Hua, Feng Wang, Bin Mao, Wei Feng, Xueren |
| description | To explore the association between genetic polymorphisms of the receptor for advanced glycation end-products (RAGE) and susceptibility, chemotherapy response rate and prognosis of non-small cell lung cancer (NSCLC).
This is a prospective study in which 562 patients with NSCLC and 764 healthy controls were enrolled. Three RAGE genetic polymorphisms, namely, -429T/C, -374T/A and 82G/S were genotyped. Platinum-based chemotherapy was given to 432 subjects with advanced inoperable NSCLC and their responses to chemotherapy were evaluated.
All the polymorphic genotypes of RAGE polymorphisms were associated with susceptibility for NSCLC. Only the 82G/S polymorphisms denoted a significant difference between responders and non-responders to chemotherapy. The 82SS genotype and 82S allele distribution not only increased the NSCLC risk, but also was associated with a lower chemotherapy response rate and poor prognosis, indicated by overall survival and progression free survival.
The 82G/S genetic polymorphism of RAGE gene might be used as a genetic marker to screen for patients sensitive to thermotherapy and to predict the prognosis of NSCLC. |
| doi_str_mv | 10.1371/journal.pone.0043734 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_plos_</sourceid><recordid>TN_cdi_plos_journals_1326720450</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A543326051</galeid><doaj_id>oai_doaj_org_article_1ae3ca9581454ea8afdaf8339529e3a9</doaj_id><sourcerecordid>A543326051</sourcerecordid><originalsourceid>FETCH-LOGICAL-c692t-21a2c57c1e98dc928fcef5d87f8df474d39a6311c2c8774f282cf6f1e4e34fa23</originalsourceid><addsrcrecordid>eNqNk11v0zAUhiMEYmPwDxBEQkIg0RJ_5OsGqarGqFQxaQNurYNznHgkcWY7Y_33uDSbWrQLlAtH9vO-58M-UfSSJHPCcvLxyoy2h3Y-mB7nScJZzvij6JiUjM4ymrDHe_9H0TPnrpIkZUWWPY2OKEtywkt6HN1eLM5O4xp79FrGg2k3nbFDo13nYrAYg3NGavBYxb-1b2Kr3a8PsWywM75BC8MmtuhCDi6wfRUP1tS9cdrFuo8H8Bp773ZSqG6gl8Ho6-VyvXwePVHQOnwxrSfR98-n35ZfZuvzs9VysZ7JrKR-RglQmeaSYFlUsqSFkqjSqshVUSme84qVkDFCJJVFnnNFCypVpghyZFwBZSfR653v0BonpqY5QRjNcprwNAnEakdUBq7EYHUHdiMMaPF3w9hagA3daVEQQCahTAvCU45QgKpAFYyVKS2RQRm8Pk3Rxp8dVjJUb6E9MD086XUjanMjGM9SlmyTeTcZWHM9ovOi005i20KPZgx5ExISTzO6jfXmH_Th6iaqhlCA7pUJceXWVCxSzgKYpCRQ8weo8FXYaRlemNJh_0Dw_kAQGI-3vobRObG6vPh_9vzHIft2j20QWt84045ehyd2CPIdKK1xzqK6bzJJxHZA7rohtgMipgEJslf7F3QvupsI9geIkQwi</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1326720450</pqid></control><display><type>article</type><title>RAGE genetic polymorphisms are associated with risk, chemotherapy response and prognosis in patients with advanced NSCLC</title><source>Public Library of Science (PLoS) Journals Open Access</source><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>Free Full-Text Journals in Chemistry</source><creator>Wang, Xiang ; Cui, Enhai ; Zeng, Huazong ; Hua, Feng ; Wang, Bin ; Mao, Wei ; Feng, Xueren</creator><creatorcontrib>Wang, Xiang ; Cui, Enhai ; Zeng, Huazong ; Hua, Feng ; Wang, Bin ; Mao, Wei ; Feng, Xueren</creatorcontrib><description>To explore the association between genetic polymorphisms of the receptor for advanced glycation end-products (RAGE) and susceptibility, chemotherapy response rate and prognosis of non-small cell lung cancer (NSCLC).
This is a prospective study in which 562 patients with NSCLC and 764 healthy controls were enrolled. Three RAGE genetic polymorphisms, namely, -429T/C, -374T/A and 82G/S were genotyped. Platinum-based chemotherapy was given to 432 subjects with advanced inoperable NSCLC and their responses to chemotherapy were evaluated.
All the polymorphic genotypes of RAGE polymorphisms were associated with susceptibility for NSCLC. Only the 82G/S polymorphisms denoted a significant difference between responders and non-responders to chemotherapy. The 82SS genotype and 82S allele distribution not only increased the NSCLC risk, but also was associated with a lower chemotherapy response rate and poor prognosis, indicated by overall survival and progression free survival.
The 82G/S genetic polymorphism of RAGE gene might be used as a genetic marker to screen for patients sensitive to thermotherapy and to predict the prognosis of NSCLC.</description><identifier>ISSN: 1932-6203</identifier><identifier>EISSN: 1932-6203</identifier><identifier>DOI: 10.1371/journal.pone.0043734</identifier><identifier>PMID: 23071492</identifier><language>eng</language><publisher>United States: Public Library of Science</publisher><subject>Advanced glycosylation end products ; Aged ; Breast cancer ; Cancer ; Cancer therapies ; Carcinoma, Non-Small-Cell Lung - drug therapy ; Carcinoma, Non-Small-Cell Lung - genetics ; Chemotherapy ; Disease ; Drug Resistance, Neoplasm ; Female ; Gastric cancer ; Gene Frequency ; Gene polymorphism ; Genes ; Genetic aspects ; Genetic markers ; Genetic polymorphisms ; Genotype ; Genotypes ; Glycosylation ; Humans ; Lung cancer ; Lung diseases ; Lung Neoplasms - drug therapy ; Lung Neoplasms - genetics ; Male ; Medical prognosis ; Medical research ; Medicine ; Metastasis ; Middle Aged ; Non-small cell lung cancer ; Non-small cell lung carcinoma ; Organoplatinum Compounds - therapeutic use ; Patients ; Platinum ; Polymorphism ; Polymorphism, Single Nucleotide ; Prognosis ; Prospective Studies ; Receptor for Advanced Glycation End Products ; Receptors, Immunologic - genetics ; Stomach cancer ; Studies ; Survival ; Thermotherapy</subject><ispartof>PloS one, 2012-10, Vol.7 (10), p.e43734-e43734</ispartof><rights>COPYRIGHT 2012 Public Library of Science</rights><rights>Wang et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License: https://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2012 Wang et al 2012 Wang et al</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c692t-21a2c57c1e98dc928fcef5d87f8df474d39a6311c2c8774f282cf6f1e4e34fa23</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3465300/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3465300/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,881,2096,2915,23845,27901,27902,53766,53768,79569,79570</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23071492$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wang, Xiang</creatorcontrib><creatorcontrib>Cui, Enhai</creatorcontrib><creatorcontrib>Zeng, Huazong</creatorcontrib><creatorcontrib>Hua, Feng</creatorcontrib><creatorcontrib>Wang, Bin</creatorcontrib><creatorcontrib>Mao, Wei</creatorcontrib><creatorcontrib>Feng, Xueren</creatorcontrib><title>RAGE genetic polymorphisms are associated with risk, chemotherapy response and prognosis in patients with advanced NSCLC</title><title>PloS one</title><addtitle>PLoS One</addtitle><description>To explore the association between genetic polymorphisms of the receptor for advanced glycation end-products (RAGE) and susceptibility, chemotherapy response rate and prognosis of non-small cell lung cancer (NSCLC).
This is a prospective study in which 562 patients with NSCLC and 764 healthy controls were enrolled. Three RAGE genetic polymorphisms, namely, -429T/C, -374T/A and 82G/S were genotyped. Platinum-based chemotherapy was given to 432 subjects with advanced inoperable NSCLC and their responses to chemotherapy were evaluated.
All the polymorphic genotypes of RAGE polymorphisms were associated with susceptibility for NSCLC. Only the 82G/S polymorphisms denoted a significant difference between responders and non-responders to chemotherapy. The 82SS genotype and 82S allele distribution not only increased the NSCLC risk, but also was associated with a lower chemotherapy response rate and poor prognosis, indicated by overall survival and progression free survival.
The 82G/S genetic polymorphism of RAGE gene might be used as a genetic marker to screen for patients sensitive to thermotherapy and to predict the prognosis of NSCLC.</description><subject>Advanced glycosylation end products</subject><subject>Aged</subject><subject>Breast cancer</subject><subject>Cancer</subject><subject>Cancer therapies</subject><subject>Carcinoma, Non-Small-Cell Lung - drug therapy</subject><subject>Carcinoma, Non-Small-Cell Lung - genetics</subject><subject>Chemotherapy</subject><subject>Disease</subject><subject>Drug Resistance, Neoplasm</subject><subject>Female</subject><subject>Gastric cancer</subject><subject>Gene Frequency</subject><subject>Gene polymorphism</subject><subject>Genes</subject><subject>Genetic aspects</subject><subject>Genetic markers</subject><subject>Genetic polymorphisms</subject><subject>Genotype</subject><subject>Genotypes</subject><subject>Glycosylation</subject><subject>Humans</subject><subject>Lung cancer</subject><subject>Lung diseases</subject><subject>Lung Neoplasms - drug therapy</subject><subject>Lung Neoplasms - genetics</subject><subject>Male</subject><subject>Medical prognosis</subject><subject>Medical research</subject><subject>Medicine</subject><subject>Metastasis</subject><subject>Middle Aged</subject><subject>Non-small cell lung cancer</subject><subject>Non-small cell lung carcinoma</subject><subject>Organoplatinum Compounds - therapeutic use</subject><subject>Patients</subject><subject>Platinum</subject><subject>Polymorphism</subject><subject>Polymorphism, Single Nucleotide</subject><subject>Prognosis</subject><subject>Prospective Studies</subject><subject>Receptor for Advanced Glycation End Products</subject><subject>Receptors, Immunologic - genetics</subject><subject>Stomach cancer</subject><subject>Studies</subject><subject>Survival</subject><subject>Thermotherapy</subject><issn>1932-6203</issn><issn>1932-6203</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><sourceid>DOA</sourceid><recordid>eNqNk11v0zAUhiMEYmPwDxBEQkIg0RJ_5OsGqarGqFQxaQNurYNznHgkcWY7Y_33uDSbWrQLlAtH9vO-58M-UfSSJHPCcvLxyoy2h3Y-mB7nScJZzvij6JiUjM4ymrDHe_9H0TPnrpIkZUWWPY2OKEtywkt6HN1eLM5O4xp79FrGg2k3nbFDo13nYrAYg3NGavBYxb-1b2Kr3a8PsWywM75BC8MmtuhCDi6wfRUP1tS9cdrFuo8H8Bp773ZSqG6gl8Ho6-VyvXwePVHQOnwxrSfR98-n35ZfZuvzs9VysZ7JrKR-RglQmeaSYFlUsqSFkqjSqshVUSme84qVkDFCJJVFnnNFCypVpghyZFwBZSfR653v0BonpqY5QRjNcprwNAnEakdUBq7EYHUHdiMMaPF3w9hagA3daVEQQCahTAvCU45QgKpAFYyVKS2RQRm8Pk3Rxp8dVjJUb6E9MD086XUjanMjGM9SlmyTeTcZWHM9ovOi005i20KPZgx5ExISTzO6jfXmH_Th6iaqhlCA7pUJceXWVCxSzgKYpCRQ8weo8FXYaRlemNJh_0Dw_kAQGI-3vobRObG6vPh_9vzHIft2j20QWt84045ehyd2CPIdKK1xzqK6bzJJxHZA7rohtgMipgEJslf7F3QvupsI9geIkQwi</recordid><startdate>20121005</startdate><enddate>20121005</enddate><creator>Wang, Xiang</creator><creator>Cui, Enhai</creator><creator>Zeng, Huazong</creator><creator>Hua, Feng</creator><creator>Wang, Bin</creator><creator>Mao, Wei</creator><creator>Feng, Xueren</creator><general>Public Library of Science</general><general>Public Library of Science (PLoS)</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>IOV</scope><scope>ISR</scope><scope>3V.</scope><scope>7QG</scope><scope>7QL</scope><scope>7QO</scope><scope>7RV</scope><scope>7SN</scope><scope>7SS</scope><scope>7T5</scope><scope>7TG</scope><scope>7TM</scope><scope>7U9</scope><scope>7X2</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABJCF</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>ATCPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>D1I</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB.</scope><scope>KB0</scope><scope>KL.</scope><scope>L6V</scope><scope>LK8</scope><scope>M0K</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>M7S</scope><scope>NAPCQ</scope><scope>P5Z</scope><scope>P62</scope><scope>P64</scope><scope>PATMY</scope><scope>PDBOC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PTHSS</scope><scope>PYCSY</scope><scope>RC3</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20121005</creationdate><title>RAGE genetic polymorphisms are associated with risk, chemotherapy response and prognosis in patients with advanced NSCLC</title><author>Wang, Xiang ; Cui, Enhai ; Zeng, Huazong ; Hua, Feng ; Wang, Bin ; Mao, Wei ; Feng, Xueren</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c692t-21a2c57c1e98dc928fcef5d87f8df474d39a6311c2c8774f282cf6f1e4e34fa23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Advanced glycosylation end products</topic><topic>Aged</topic><topic>Breast cancer</topic><topic>Cancer</topic><topic>Cancer therapies</topic><topic>Carcinoma, Non-Small-Cell Lung - drug therapy</topic><topic>Carcinoma, Non-Small-Cell Lung - genetics</topic><topic>Chemotherapy</topic><topic>Disease</topic><topic>Drug Resistance, Neoplasm</topic><topic>Female</topic><topic>Gastric cancer</topic><topic>Gene Frequency</topic><topic>Gene polymorphism</topic><topic>Genes</topic><topic>Genetic aspects</topic><topic>Genetic markers</topic><topic>Genetic polymorphisms</topic><topic>Genotype</topic><topic>Genotypes</topic><topic>Glycosylation</topic><topic>Humans</topic><topic>Lung cancer</topic><topic>Lung diseases</topic><topic>Lung Neoplasms - drug therapy</topic><topic>Lung Neoplasms - genetics</topic><topic>Male</topic><topic>Medical prognosis</topic><topic>Medical research</topic><topic>Medicine</topic><topic>Metastasis</topic><topic>Middle Aged</topic><topic>Non-small cell lung cancer</topic><topic>Non-small cell lung carcinoma</topic><topic>Organoplatinum Compounds - therapeutic use</topic><topic>Patients</topic><topic>Platinum</topic><topic>Polymorphism</topic><topic>Polymorphism, Single Nucleotide</topic><topic>Prognosis</topic><topic>Prospective Studies</topic><topic>Receptor for Advanced Glycation End Products</topic><topic>Receptors, Immunologic - genetics</topic><topic>Stomach cancer</topic><topic>Studies</topic><topic>Survival</topic><topic>Thermotherapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wang, Xiang</creatorcontrib><creatorcontrib>Cui, Enhai</creatorcontrib><creatorcontrib>Zeng, Huazong</creatorcontrib><creatorcontrib>Hua, Feng</creatorcontrib><creatorcontrib>Wang, Bin</creatorcontrib><creatorcontrib>Mao, Wei</creatorcontrib><creatorcontrib>Feng, Xueren</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Gale In Context: Opposing Viewpoints</collection><collection>Gale In Context: Science</collection><collection>ProQuest Central (Corporate)</collection><collection>Animal Behavior Abstracts</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Nursing & Allied Health Database</collection><collection>Ecology Abstracts</collection><collection>Entomology Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Meteorological & Geoastrophysical Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Agricultural Science Collection</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Materials Science & Engineering Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>Advanced Technologies & Aerospace Collection</collection><collection>Agricultural & Environmental Science Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Materials Science Collection</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Materials Science Database</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Meteorological & Geoastrophysical Abstracts - Academic</collection><collection>ProQuest Engineering Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Agricultural Science Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Engineering Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Advanced Technologies & Aerospace Database</collection><collection>ProQuest Advanced Technologies & Aerospace Collection</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Environmental Science Database</collection><collection>Materials Science Collection</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Engineering Collection</collection><collection>Environmental Science Collection</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>PloS one</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wang, Xiang</au><au>Cui, Enhai</au><au>Zeng, Huazong</au><au>Hua, Feng</au><au>Wang, Bin</au><au>Mao, Wei</au><au>Feng, Xueren</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>RAGE genetic polymorphisms are associated with risk, chemotherapy response and prognosis in patients with advanced NSCLC</atitle><jtitle>PloS one</jtitle><addtitle>PLoS One</addtitle><date>2012-10-05</date><risdate>2012</risdate><volume>7</volume><issue>10</issue><spage>e43734</spage><epage>e43734</epage><pages>e43734-e43734</pages><issn>1932-6203</issn><eissn>1932-6203</eissn><abstract>To explore the association between genetic polymorphisms of the receptor for advanced glycation end-products (RAGE) and susceptibility, chemotherapy response rate and prognosis of non-small cell lung cancer (NSCLC).
This is a prospective study in which 562 patients with NSCLC and 764 healthy controls were enrolled. Three RAGE genetic polymorphisms, namely, -429T/C, -374T/A and 82G/S were genotyped. Platinum-based chemotherapy was given to 432 subjects with advanced inoperable NSCLC and their responses to chemotherapy were evaluated.
All the polymorphic genotypes of RAGE polymorphisms were associated with susceptibility for NSCLC. Only the 82G/S polymorphisms denoted a significant difference between responders and non-responders to chemotherapy. The 82SS genotype and 82S allele distribution not only increased the NSCLC risk, but also was associated with a lower chemotherapy response rate and poor prognosis, indicated by overall survival and progression free survival.
The 82G/S genetic polymorphism of RAGE gene might be used as a genetic marker to screen for patients sensitive to thermotherapy and to predict the prognosis of NSCLC.</abstract><cop>United States</cop><pub>Public Library of Science</pub><pmid>23071492</pmid><doi>10.1371/journal.pone.0043734</doi><tpages>e43734</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1932-6203 |
| ispartof | PloS one, 2012-10, Vol.7 (10), p.e43734-e43734 |
| issn | 1932-6203 1932-6203 |
| language | eng |
| recordid | cdi_plos_journals_1326720450 |
| source | Public Library of Science (PLoS) Journals Open Access; MEDLINE; DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; Free Full-Text Journals in Chemistry |
| subjects | Advanced glycosylation end products Aged Breast cancer Cancer Cancer therapies Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - genetics Chemotherapy Disease Drug Resistance, Neoplasm Female Gastric cancer Gene Frequency Gene polymorphism Genes Genetic aspects Genetic markers Genetic polymorphisms Genotype Genotypes Glycosylation Humans Lung cancer Lung diseases Lung Neoplasms - drug therapy Lung Neoplasms - genetics Male Medical prognosis Medical research Medicine Metastasis Middle Aged Non-small cell lung cancer Non-small cell lung carcinoma Organoplatinum Compounds - therapeutic use Patients Platinum Polymorphism Polymorphism, Single Nucleotide Prognosis Prospective Studies Receptor for Advanced Glycation End Products Receptors, Immunologic - genetics Stomach cancer Studies Survival Thermotherapy |
| title | RAGE genetic polymorphisms are associated with risk, chemotherapy response and prognosis in patients with advanced NSCLC |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-14T08%3A44%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_plos_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=RAGE%20genetic%20polymorphisms%20are%20associated%20with%20risk,%20chemotherapy%20response%20and%20prognosis%20in%20patients%20with%20advanced%20NSCLC&rft.jtitle=PloS%20one&rft.au=Wang,%20Xiang&rft.date=2012-10-05&rft.volume=7&rft.issue=10&rft.spage=e43734&rft.epage=e43734&rft.pages=e43734-e43734&rft.issn=1932-6203&rft.eissn=1932-6203&rft_id=info:doi/10.1371/journal.pone.0043734&rft_dat=%3Cgale_plos_%3EA543326051%3C/gale_plos_%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1326720450&rft_id=info:pmid/23071492&rft_galeid=A543326051&rft_doaj_id=oai_doaj_org_article_1ae3ca9581454ea8afdaf8339529e3a9&rfr_iscdi=true |